NEW YORK (GenomeWeb News) - Ibis Biosciences, a subsidiary of Isis Pharmaceuticals, said yesterday that has been awarded a $1.2 million subcontract from the National Institutes of Health to study how influenza viruses are transmitted.
Ibis is conducting the research through a subcontract with its partner the Lovelace Respiratory Research Institute. The grant will sponsor assay development and sample characterization for viruses including the H5N1 strain, which causes avian flu.
Ibis will use its T5000 Biosensor System and a methodology called Triangulation Identification for the Genetic Evaluation of Risks, which it said is “a combination of genomics, mathematical modeling, mass spectrometry and molecular amplification.”
The expanded influenza detection assays Ibis and LRRI plan to develop will “uniquely identify and characterize influenza strains and aid in the tracking of influenza transmissions,” the company said.